RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)

Inclusion Criteria: * Healthy infants, aged from 6 weeks through full 7 weeks, * Consent form signed by at least one parent or by the legal representative properly informed about the study, * Parent(s) / legal representative able to understand the protocol requirements and to fill in the Diary Card. Exclusion Criteria: * History of congenital abdominal disorders, congenital malformation of the gastrointestinal tract that could predispose to intussusception, or abdominal surgery, * Congenital fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency, * Known or suspected impairment of immunological function, * Known hypersensitivity to any component of RotaTeq® (e.g. sucrose) or of NeisVac-C® (including tetanus toxoid), * Prior administration of any rotavirus vaccine, * Prior administration of any vaccine within the 28 days prior to randomisation, * Fever (rectal temperature ≥38.1°C) and/or acute diarrhoea and/or vomiting at randomisation, * History of known prior rotavirus gastroenteritis, chronic diarrhoea, or failure to thrive, * Any severe thrombocytopenia or any other coagulation disorder that would contraindicate intramuscular injection, * Clinical evidence of active gastrointestinal illness, * Receipt of intramuscular, oral, or intravenous corticosteroid treatment within the 14 days prior to randomisation. Note: Infants on inhaled and/or topical steroids may participate in the study, * Infants residing in a household with an immunocompromised person, * Prior receipt of a blood transfusion or blood products, including immunoglobulins.